Chiara Tolassi

Dr. Chiara Tolassi

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 April 2025 in Nature Medicine
Verified
Journal Article
Open access
SPSebastian Palmqvist
Sebastian Palmqvist
NWNoëlle Warmenhoven
Noëlle Warmenhoven
Federica AnastasiFederica Anastasi
Federica Anastasi
APAndrea Pilotto
Andrea Pilotto
SJShorena Janelidze
Shorena Janelidze
OHOskar Hansson
Oskar Hansson
Global implementation of blood tests for Alzheimer’s disease (AD) would be facilitated by easily scalable, cost-effective and accurate tests. In the present study, we evaluated plasma phospho-tau217 (p-tau217) using predefined biomarker cutoffs. The study included 1,767 participants with cognitive symptoms from 4 independent secondary care cohorts in Malmö (Sweden, n = 337), Gothenburg (Sweden, n = 165), Barcelona (Spain, n = 487) and Brescia (Italy, n = 230), and a primary care cohort in Sweden ( n = 548). Plasma p-tau217 was primarily measured using the fully automated, commercially available, Lumipulse immunoassay. The primary outcome was AD pathology defined as abnormal cerebrospinal fluid Aβ42:p-tau181. Plasma p-tau217 detected AD pathology with areas under the receiver operating characteristic curves of 0.93–0.96. In secondary care, the accuracies were 89–91%, the positive predictive values 89–95% and the negative predictive values 77–90%. In primary care, the accuracy was 85%, the positive predictive values 82% and the negative predictive values 88%. Accuracy was lower in participants aged ≥80 years (83%), but was unaffected by chronic kidney disease, diabetes, sex, APOE genotype or cognitive stage. Using a two-cutoff approach, accuracies increased to 92–94% in secondary and primary care, excluding 12–17% with intermediate results. Using the plasma p-tau217:Aβ42 ratio did not improve accuracy but reduced intermediate test results (≤10%). Compared with a high-performing mass-spectrometry-based assay for percentage p-tau217, accuracies were comparable in secondary care. However, percentage p-tau217 had higher accuracy in primary care and was unaffected by age. In conclusion, this fully automated p-tau217 test demonstrates high accuracy for identifying AD pathology. A two-cutoff approach might be necessary to optimize performance across diverse settings and subpopulations.

Verified
Journal Article
Open access
PDF file
ALAntonio Longobardi
Antonio Longobardi
SBSonia Bellini
Sonia Bellini
RNRoland Nicsanu
Roland Nicsanu
APAndrea Pilotto
Andrea Pilotto
AGAndrea Geviti
Andrea Geviti
RGRoberta Ghidoni
Roberta Ghidoni
Alzheimer’s disease (AD) and Frontotemporal lobar degeneration (FTLD) represent the most common forms of neurodegenerative dementias with a highly phenotypic variability. Herein, we investigated the role of genetic variants related to the immune system and inflammation as genetic modulators in AD and related dementias. In patients with sporadic AD/FTLD (n = 300) and GRN/C9orf72 mutation carriers (n = 80), we performed a targeted sequencing of 50 genes belonging to the immune system and inflammation, selected based on their high expression in brain regions and low tolerance to genetic variation. The linear regression analyses revealed two genetic variants: (i) the rs1049296 in the transferrin (TF) gene, shown to be significantly associated with age at onset in the sporadic AD group, anticipating the disease onset of 4 years for each SNP allele with respect to the wild-type allele, and (ii) the rs7550295 in the calsyntenin-1 (CLSTN1) gene, which was significantly associated with age at onset in the C9orf72 group, delaying the disease onset of 17 years in patients carrying the SNP allele. In conclusion, our data support the role of genetic variants in iron metabolism (TF) and in the modulation of the calcium signalling/axonal anterograde transport of vesicles (CLSTN1) as genetic modulators in AD and FTLD due to C9orf72 expansions.

24 June 2026 in medRxiv
Verified
Preprint
Open access
TMTommaso Merati
Tommaso Merati
CTChiara Tolassi
Chiara Tolassi
Alessandro RondinaAlessandro Rondina
Alessandro Rondina
IGIrene Girotto
Irene Girotto
MBMarianna Bertoni
Marianna Bertoni
APAlessandro Padovani
Alessandro Padovani
Blood-based proteomic profiling is now widely applied in neurodegenerative and neuroinflammatory disease, yet the choice between serum and plasma remains poorly characterised for high-multiplex platforms. Many legacy biobanks hold mainly serum, whereas most current NUcleic-acid-Linked Immuno-Sandwich Assay (NULISA) studies use plasma. We compared the 130-protein NULISAseq central nervous system (CNS) Disease Panel head-to-head in matched serum and plasma collected at the same draw from 62 participants (30 neurodegenerative, 19 demyelinating, 13 healthy controls). Agreement was measured with Spearman correlation (rho), Lin’s concordance correlation coefficient (CCC), the intraclass correlation coefficient (ICC) and the mean paired serum-to-plasma difference (dNPQ). Concordance was moderate to high: 123 of 130 proteins reached significance and 18 reached rho >= 0.90, with a median rho of 0.72 (range 0.10-0.988). Proteins fell into three tiers. Cytoskeletal markers (NEFH rho=0.988; NEFL rho=0.947) and glial GFAP (rho=0.949, |dNPQ|<0.5) were interchangeable between matrices. Phosphorylated tau (pTau) species retained excellent rank concordance but carried a systematic plasma-greater-than-serum offset (pTau-181 rho=0.869, dNPQ=+0.67; pTau-217 rho=0.846, dNPQ=+0.64; pTau-231 rho=0.885, dNPQ=+0.89). Platelet-derived analytes (CD40LG rho=0.102, dNPQ=-4.74; BDNF rho=0.223, dNPQ=-2.69) and intracellular synaptic proteins (NRGN, SNAP25, ENO2) diverged markedly. For most clinically relevant neurodegeneration markers, especially cytoskeletal and glial proteins, serum is a valid substitute for plasma; absolute thresholds for phosphorylated tau and amyloid peptides require matrix-specific calibration, and platelet-sensitive analytes cannot be compared across matrices without strictly standardised pre-analytical conditions. Main Points: Across the 130-protein NULISAseq CNS Disease Panel, serum and plasma showed moderate-to-high overall concordance (median Spearman rho 0.72; 123/130 proteins significant). Neurofilaments (NEFH, NEFL) and GFAP were interchangeable between matrices, whereas phosphorylated tau species retained rank order but required matrix-specific calibration of absolute levels. Platelet-derived (CD40LG, BDNF) and intracellular synaptic proteins (NRGN, SNAP25, ENO2) were not comparable across matrices without strict pre-analytical standardisation.

25 August 2026 in Scientific Reports
Verified
Journal Article
Open access
PDF file
CTChiara Trasciatti
Chiara Trasciatti
APAndrea Pilotto
Andrea Pilotto
CTChiara Tolassi
Chiara Tolassi
FRFlavio Ragni
Flavio Ragni
EMElena Marcello
Elena Marcello
APAlessandro Padovani
Alessandro Padovani
Alzheimer’s disease (AD) is characterized by complex alterations in synaptic, glial, neuronal and inflammatory markers. Given its emerging role at the interface of synaptic dysfunction and inflammation, the astrocytic marker GFAP may represent a cross-domain hub linking synaptic, neuronal and inflammatory alterations. Using multivariate and network-based analyses we examined the relationships among cerebrospinal fluid (CSF) biomarkers of astrocytic activation and synaptic failure, inflammation, and neurodegeneration in biologically confirmed AD patients and healthy controls (HC). We studied 60 AD patients and 40 HC. CSF concentrations of neurogranin, SNAP-25, CAP2, NfL, GFAP, IL-1α, IL-1β, IL-8, MCP-1, TNF-α were measured. Associations were assessed using Spearman correlations, LASSO regression, and network analysis to characterize multivariate dependency structures. Compared with controls, AD patients showed significantly higher CSF levels of neurogranin, SNAP-25, CAP2, NfL, GFAP, IL-1β, TNF-α. In AD, synaptic biomarkers were strongly intercorrelated and associated with astroglial activation, inflammatory markers, and tau-related pathology. Network analysis identified GFAP as a cross-domain hub linking synaptic, inflammatory, and neurodegenerative domains in AD. In controls, GFAP was mainly associated with neuronal injury markers. Network-based modelling revealed a disease-related reorganization of biomarker connectivity in AD, with GFAP occupying a central cross-domain position, supporting a systems-level view of AD pathophysiology.

5 November 2026 in Journal of Neurochemistry
Verified
Journal Article
Closed access
TMTommaso Merati
Tommaso Merati
CTChiara Tolassi
Chiara Tolassi
ARAlessandro Rondina
Alessandro Rondina
IGIrene Girotto
Irene Girotto
MBMarianna Bertoni
Marianna Bertoni
APAlessandro Padovani
Alessandro Padovani

25 June 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
ATAndrea Toja
Andrea Toja
EREqrem Rusi
Eqrem Rusi
CTChiara Tolassi
Chiara Tolassi
AGAlice Galli
Alice Galli
CTChiara Trasciatti
Chiara Trasciatti
APAlessandro Padovani
Alessandro Padovani
Background: Plasma phosphorylated tau (p-tau) isoforms are established biomarkers of Alzheimer’s disease (AD), but whether their combined elevation reflects biological heterogeneity within AD remains unclear.Objective: To determine whether distinct plasma p-tau217, p-tau181, and p-tau231 profiles identify clinically and biologically meaningful severity strata within biologically confirmed AD.Methods: We included 106 patients with CSF-confirmed AD at the mild cognitive impairment or dementia stage. Participants underwent clinical assessment, CSF Aβ42 and tau biomarker measurement, and plasma assessment of p-tau217, p-tau181, p-tau231, Aβ42/Aβ40, GFAP, and NfL. Longitudinal MMSE data were available in 80 participants over a mean 2.6-year follow-up. Patients were classified using ROC-derived multi-isoform profiles and, separately, p-tau217 quintiles. Clinical and biological group differences and age- and sex-adjusted regression models were evaluated.Results: Multi-isoform profiling identified five profiles, ranging from all-intermediate p-tau isoforms to triple-high. Compared with the all-intermediate profile, profiles with broader p-tau isoform elevation showed higher CSF tau markers, higher plasma GFAP and NfL, and faster annualized MMSE decline. The triple-high profile showed worst cognitive performance and highest plasma biomarker burden. Complementary p-tau217 quintile stratification showed a parallel severity gradient, with higher quintiles associated with increased CSF tau markers, GFAP, NfL, and cognitive decline. Regression analyses supported p-tau217 as the strongest single-marker correlate, whereas p-tau231 contributed to NfL and CSF t-tau models.Conclusions: Multi-isoform plasma p-tau profiling identifies biologically distinct AD severity strata, consistent with a hierarchy of increasing tau phosphorylation burden. p-tau217 captures much of this continuum and remains the most robust single-marker correlate, whereas p-tau231 may provide complementary information on neurodegeneration-related biology.